title: Riluzole and D-amphetamine interactions in humans.
abstract: In preclinical studies, medications which decrease glutamate release have been shown to block some of the effects of psychostimulants. One such medication is riluzole, marketed for the treatment of Amyotrophic Lateral Sclerosis (ALS). The goal of this study was to determine riluzole's effects on acute physiological and subjective responses to d-amphetamine in healthy volunteers. Seven male and 5 female subjects participated in an outpatient double-blind, placebo-controlled, crossover study. Across 4 sessions, subjects were randomly assigned to a sequence of 4 oral treatments: placebo, 20 mg D-amphetamine alone, 100 mg riluzole alone, or d-amphetamine plus riluzole. Outcome measures included heart rate, blood pressure, plasma cortisol, performance on the Sustained Attention to Response Test (SART), and subjective measures. d-amphetamine increased heart rate, blood pressure and plasma cortisol levels while inducing psychostimulant-type subjective effects. On the SART, d-amphetamine enhanced the speed of correct responses but also significantly increased the number of errors of commission. Riluzole at 100 mg did not block, the typical subjective and physiological responses to 20 mg D-amphetamine. Riluzole alone induced amphetamine-like subjective responses. On the SART test, riluzole increased the number errors of commission, but unlike d-amphetamine, did not speed reaction time. The mechanism accounting for these findings is unclear, but may involve processes other than decreased glutamate release by riluzole. The effects of glutamate medications on psychostimulant responses need to be further examined.
authors: Yale University, School of Medicine, Department of Psychiatry and VA Connecticut Healthcare System, 950 Campbell Ave., Bldg. 36/116A4, West Haven, CT 06516, United States. Mehmet.Sofuoglu@yale.edu
authors: Mehmet
authors: M
authors: Sofuoglu
authors: Andrew J
authors: AJ
authors: Waters
authors: Marc
authors: M
authors: Mooney
authors: Thomas
authors: T
authors: Kosten
mesh_terms: D000328:Adult; D019540:Area Under Curve; D001794:Blood Pressure / Q000187:drug effects; D000697:Central Nervous System Stimulants / Q000494:pharmacology*; D003071:Cognition / Q000187:drug effects; D018592:Cross-Over Studies; D003913:Dextroamphetamine / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004347:Drug Interactions / Q000502:physiology*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D009483:Neuropsychological Tests; D017063:Outcome Assessment, Health Care / Q000379:methods; D011930:Reaction Time / Q000187:drug effects; D019782:Riluzole / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D000697:Central Nervous System Stimulants; D019782:Riluzole; D003913:Dextroamphetamine; D006854:Hydrocortisone
references: Brain Res. 1994 Jan 7;633(1-2):312-6
references: 7907936
references: Annu Rev Pharmacol Toxicol. 1993;33:639-77
references: 8494354
references: Biol Psychiatry. 1996 Jan 1;39(1):26-32
references: 8719123
references: Psychiatry Res. 1996 Aug 30;64(1):1-10
references: 8888359
references: Neurology. 1996 Dec;47(6 Suppl 4):S233-41
references: 8959995
references: Neuropsychologia. 1997 Jun;35(6):747-58
references: 9204482
references: Crit Rev Neurobiol. 1998;12(1-2):37-67
references: 9444481
references: Neurosci Lett. 1998 Feb 13;242(2):114-6
references: 9533407
references: J Clin Psychopharmacol. 2004 Dec;24(6):665-9
references: 15538132
references: Drug Alcohol Depend. 2005 Feb 14;77(2):151-9
references: 15664716
references: Biol Psychiatry. 2005 Feb 15;57(4):430-2
references: 15705360
references: J Comp Neurol. 2005 Mar 28;484(1):43-56
references: 15717303
references: J Neurosci. 2005 Aug 10;25(32):7342-51
references: 16093384
references: J Subst Abuse Treat. 2005 Sep;29(2):85-93
references: 16135337
references: Biol Psychiatry. 2005 Sep 1;58(5):424-8
references: 15993857
references: Alcohol Clin Exp Res. 2006 Sep;30(9):1451-65
references: 16930207
references: Psychopharmacology (Berl). 2006 Oct;188(2):162-70
references: 16915378
references: Neuropsychopharmacology. 2007 Apr;32(4):793-802
references: 16936714
references: Lancet. 2003 May 31;361(9372):1878-9
references: 12788585
references: Psychopharmacology (Berl). 2000 Aug;151(2-3):226-33
references: 10972469
references: Prog Neurobiol. 2001 Feb;63(3):241-320
references: 11115727
references: Neuropsychobiology. 2001;43(2):91-5
references: 11174052
references: Psychopharmacology (Berl). 2000 Dec;153(1):85-92
references: 11255931
references: Neuropsychologia. 2002;40(1):1-6
references: 11595257
references: J Subst Abuse Treat. 2001 Dec;21(4):193-8
references: 11777668
references: Arch Gen Psychiatry. 2002 May;59(5):409-16
references: 11982444
references: Dev Neuropsychol. 2002;21(1):43-71
references: 12058835
references: J Pharmacol Exp Ther. 2002 Sep;302(3):1265-71
references: 12183688
references: Nature. 2003 Jan 2;421(6918):70-5
references: 12511956
references: J Neuropsychiatry Clin Neurosci. 2003 Winter;15(1):98-104
references: 12556579
references: Mol Psychiatry. 2003 Apr;8(4):373-82
references: 12740594
references: Neuropsychobiology. 2003;48(1):27-30
references: 12886037
references: Drug Alcohol Depend. 2003 Aug 20;71(2):143-52
references: 12927652
references: J Neurosci. 2003 Oct 22;23(29):9500-7
references: 14573529
references: Ann N Y Acad Sci. 2003 Nov;1003:169-75
references: 14684444
references: Neuron. 2004 Sep 30;44(1):161-79
references: 15450168
references: Am J Psychiatry. 2004 Nov;161(11):2132
references: 15514421
references: Ann N Y Acad Sci. 1992 Jun 28;654:171-91
references: 1632582
references: Psychopharmacology (Berl). 1993;111(1):1-16
references: 7870923